Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX

Sei Investments Co. raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 128.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 82,108 shares of the company’s stock after buying an additional 46,132 shares during the quarter. Sei Investments Co. owned 0.08% of Nurix Therapeutics worth $1,273,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. General Atlantic L.P. acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth about $92,899,000. Morgan Stanley raised its position in shares of Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after acquiring an additional 2,620,323 shares during the period. Rubric Capital Management LP bought a new position in Nurix Therapeutics during the 4th quarter worth approximately $46,930,000. Braidwell LP bought a new position in Nurix Therapeutics during the 4th quarter worth approximately $41,428,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Nurix Therapeutics by 195.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock valued at $61,622,000 after purchasing an additional 2,149,268 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. This represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the completion of the sale, the insider owned 117,227 shares in the company, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,314 shares of company stock worth $589,361 over the last ninety days. 6.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group upped their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada lifted their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday. Truist Financial boosted their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer assumed coverage on shares of Nurix Therapeutics in a research report on Monday, June 29th. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, Stifel Nicolaus raised their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.21.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $25.96 on Wednesday. The company has a market capitalization of $2.69 billion, a P/E ratio of -7.52 and a beta of 1.79. The company’s 50 day moving average price is $21.62 and its two-hundred day moving average price is $18.15. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $26.36.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The company had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Analysts forecast that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.